Eli Lilly, the drugmaker with two weight-loss bestsellers, just got its first dose of healthy skeptism during a time when the ...

Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral ...

On Friday, Mad Money host Jim Cramer took a close look at what he called one of the most important stretches of the earnings ...

New Integration with Gifthealth Simplifies Fulfillment and Medication Visibility for WeightWatchers Clinic MembersNEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- WeightWatchers (NASDAQ: WW) ...

Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.62 billion and $3.52 per share, ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Hims & Hers Health (HIMS) stock surges following a partnership with Novo Nordisk (NVO) to sell the Danish drugmaker's weight ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

TUCSON, AZ / ACCESS Newswire / April 29, 2025 / Retatrutide, also known as LY3437943, is an innovative triple receptor agonist targeting glucose-dependent insulinotropic polypeptide (GIP), ...

A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.

Home > Pressemitteilung: GIP Receptor: Activation and Blockade ...

The first reveal of clinical data with Eli Lilly’s injectable ... GIP and GLP-1 – the same as Lilly’s fast-growing diabetes therapy Mounjaro (tirzepatide) – but adds in activity against ...